Table 3.

Method 2 (DLDA) analysis of leukemia/lymphoma predictor genes

Affymetrix IDMethod 1 genes (87%)*SymbolGene functionFold change
201828_x_atcaax box 1FAM127Aplasma membrane4.8
205691_atsynaptogyrin 3SYNGR3plasma membrane8.6
207180_s_athiv-1 tat interactive protein 2, 30kdaHTATIP2cell cycle, transcription, apoptosis3.0
208796_s_atcyclin g1CCNG1regulation of cell cycle,2.1
209116_x_athemoglobin, βHBBcirculatory system process18.9
211560_s_ataminolevulinate, δ-, synthase 2 (sideroblastic/hypochromic anemia)ALAS2response to hypoxia, immune response3.3
214696_atchromosome 17 open reading frame 91C17orf912.8
217650_x_atst3 β-galactoside α-2,3-sialyltransferase 2ST3GAL2carbohydrate metabolism2.3
Affymetrix IDMethod 2 genes (82%)SymbolGene functionFold change
201029_s_atcd99 antigenCD99cell adhesion−2.2
201288_atrho gdp dissociation inhibitor βARHGDIBimmune response, Rho/Ras signaling−2.3
201310_s_atchromosome 5 open reading frame 13C5orf13cell communication−5.9
201347_x_atglyoxylate reductase/hydroxypyruvate reductaseGRHPRmetabolic process2.1
206660_atimmunoglobulin λ-like polypeptide 1IGLL1immune response−44.7
208892_s_atdual specificity phosphatase 6DUSP6cell cycle, inactivation of mitogen-activated protein kinase activity−2.2
209806_athistone 1, h2bkHIST1H2BKnucleosome assembly5.1
209942_x_atmelanoma antigen family a, 3MAGEA3tumor antigen26.3
211921_x_atprothymosin, αPTMAcell cycle, transcription−1.6
213515_x_athemoglobin, γ aHBG2oxygen transport138.2
Affymetrix IDBcl-2 family genes (81%)SymbolGene functionFold change
200796_s_atmyeloid cell leukemia sequence 1 (bcl2-related)MCL1apoptosis1.8
200797_s_atmyeloid cell leukemia sequence 1 (bcl2-related)MCL1apoptosis1.4
200798_x_atmyeloid cell leukemia sequence 1 (bcl2-related)MCL1apoptosis1.7
203684_s_atb-cell cll/lymphoma 2BCL2apoptosis−1.7
204493_atbh3 interacting domain death agonistBIDapoptosis−1.2
206665_s_atbcl2-like 1(Bcl-xL)BCL2L1apoptosis2.6
209311_atbcl2-like 2 (Bcl-w)BCL2L2apoptosis2.6
211692_s_atbcl2 binding component 3 (Puma)BBC3apoptosis2.2
  • *Genes from the leukemia/lymphoma discriminant predictor sets (Method 1) were combined and processed by DLDA (Method 2), with the best sets shown. The percentage of arrays correctly identified is shown for the sets listed, with the fold change in resistant compared with sensitive lines.

  • The best DLDA predictor gene set is shown for all of the genes, as well as the Bcl-2 family genes.